Clinical trials: Blood Plasma Therapy
Multiple Myeloma, Heart Disease Risk Factors
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
People with multiple myeloma may have health conditions or receive treatments that increase their risk of heart and blood-vessel problems.
- Trial name
- MM-CARE (NCT07783607)
- Testing
- Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Vermont Medical Center
Relapsed/Refractory Multiple Myeloma
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-1 (NCT05850234)
- Testing
- AZD0120
- Where
- 36 sites in United States
- Volunteers
- 232 people
- Sponsor
- AstraZeneca
Optic Neuritis, Neuromyelitis Optica
Optic Neuritis Differential Diagnosis Study
Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds.
- Conditions
- Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis
- Trial name
- ONDDS (NCT03370965)
- Testing
- Neuro-ophtalmology examination
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital Center of Martinique
HIV Infection
Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection
The investigators have previously described a limited group of HIV-1-infected patients, we called HIV controllers (HIC), who have been infected for more than 10 years, in whom viral replication is spontaneously controlled without…
- Trial name
- ANRS CO18 (NCT01065207)
- Testing
- blood test at day one
- Where
- France
- Volunteers
- 250 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Striae Distensae
PRP vs PRF in Management of Striae Distensae
A split-side comparative clinical study evaluating the efficacy and safety of injectable platelet-rich fibrin (PRF) versus platelet-rich plasma (PRP), alone or combined with microneedling, in the treatment of striae distensae.
- Trial name
- NCT07561671
- Testing
- PRF group, PRP injection, PRF and microneedling
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Zagazig University
Multiple Myeloma
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of…
- Trial name
- iMMagine-3 (NCT06413498)
- Testing
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 452 people
- Sponsor
- Kite, A Gilead Company
COVID-19, Convalescent Plasma Treatment
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica
Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection.
- Trial name
- NCT04644198
- Testing
- Convalescent Plasma Infusion
- Where
- Jamaica
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The University of The West Indies
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma.
- Trial name
- NCT00006232
- Testing
- dexamethasone, doxorubicin hydrochloride, idarubicin
- Where
- 12 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- West of Scotland Lymphoma Group
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Gastro Esophageal Reflux
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)
This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e.
- Trial name
- AREA21 (NCT05570448)
- Testing
- ARAT
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Midwest Veterans' Biomedical Research Foundation
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma.
- Trial name
- NCT05497804
- Testing
- Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Tumor Lysis Syndrome, Cancer
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
This is a randomized, multi-center, open-label, parallel group study with three arms: Rasburicase alone Rasburicase followed by Allopurinol Allopurinol alone The primary objective is to compare the adequacy of control of plasma…
- Conditions
- Tumor Lysis Syndrome, Cancer, Hyperuricemia
- Trial name
- NCT00230178
- Testing
- Rasburicase (SR29142), Allopurinol
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Sanofi
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Acute-On-Chronic Liver Failure, Acute on Chronic Hepatic Failure
The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients
Acute liver failure patients posed high mortality rate despite receiving standard therapy. The severity and mortality even higher in patients with underlying liver disease.
- Trial name
- NCT05030571
- Testing
- DPMAS, standard treatment
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Chulalongkorn University
Waldenstroms Macroglobulinemia
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
This is a Phase II multicenter study designed to evaluate the safety and efficacy of combination BDR. BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM.
- Trial name
- BDR-WM (NCT00832234)
- Testing
- Bortezomib, Dexamethasone, Rituximab
- Where
- Greece
- Volunteers
- 59 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
GEM05 for Patients With Multiple Myeloma Under 65 Years
The primary objective is to compare safety and efficacy of three induction treatments: VBMCP-VBAD / Velcade versus Thalidomide / Dexamethasone versus Velcade / Thalidomide / Dexamethasone.
- Trial name
- GEM05MENOS65 (NCT00461747)
- Testing
- VBMCP/VBAD/Velcade, Thalidomide/Dexamethasone, Velcade/Thalidomide/Dexamethasone
- Where
- 79 sites in Spain
- Volunteers
- 390 people
- Sponsor
- PETHEMA Foundation
Periorbital Hypermelanosis
Evaluation of the Therapeutic Effect of Platelet Rich Plasma (PRP) in Periorbital Hyperpigmentation(POH)
To evaluate the saftey and efficicacy of autologous PRP in treatment of POH.
- Trial name
- NCT03862118
- Testing
- PRP
- Volunteers
- 30 people
- Sponsor
- Assiut University
Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
The goal of this clinical trial is to assess the safety and effects of a crystallized form of lithium, AL001, when compared to commonly used lithium carbonate in individuals diagnosed with bipolar I disorder.
- Trial name
- NCT07540338
- Testing
- AL001, Lithium carbonate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alzamend Neuro, Inc.
Persistent Epithelial Defect
Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects
Persistent epithelial defects (PED) are corneal ulcers that do not heal within the first two weeks of treatment with artificial tears or ocular lubricant ointment.
- Trial name
- NCT03653650
- Testing
- PRP plus BCL, BCL plus PFL, Eye patch plus ocular lubricant ointment
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.